Amarin's Vascepa Shows Reduced Cardiovascular Events in Kidney Patients in Latest Study

Amarin (NASDAQ: AMRN) released clinical trial results Monday that showed its Vascepa heart medicine effectively reduced cardiovascular events in patients with decreased kidney function. The late-stage trial is a component of the company's REDUCE-IT studies aimed at gauging Vascepa's effect on at-risk patient populations. "We continue to see the consistency in benefit and safety of Vascepa administration across various at-risk patient populations, including across varying degrees of renal function," the company quoted its chief scientific officer, Steven Ketchum, as saying.